about
Characterization of human vaginal mucosa cells for autologous in vitro cultured vaginal tissue transplantation in patients with MRKH syndrome.Weekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis.Perivascular epithelioid cell neoplasm (PEComa) of the uterus: A systematic review.Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies.Ixabepilone for the treatment of endometrial cancer.Bevacizumab in Ovarian Cancer: State of the Art and Unanswered Questions.Type B versus Type C Radical Hysterectomy After Neoadjuvant Chemotherapy in Locally Advanced Cervical Carcinoma: A Propensity-Matched Analysis.Cryopreservation protocol for human biliary tree stem/progenitors, hepatic and pancreatic precursorsSecondary Cytoreduction in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Institution Experience.Severe pelvic organ prolapse treated by vaginal native tissue repair: long-term analysis of outcomes in 146 patients.Sexual Health and Quality of Life Assessment among Ovarian Cancer Patients during Chemotherapy.Effects of Neoadjuvant Chemotherapy Plus Radical Surgery as Front Line Treatment Strategy in Patients Affected by FIGO Stage III Cervical Cancer.Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms.Postpartum Posterior Reversible Encephalopathy Syndrome (PRES): Three Case Reports and Literature ReviewWhite Leopard Skin Pattern at Hysteroscopy in a Case of HematometraShort-Infusion Trabectedin in Heavily Pretreated Ovarian Cancer Patients: A Single-Institution Experience
P50
Q34069635-933AA8F8-5C60-42C2-A7B3-674440A08CC5Q37629090-CCD2B945-6D08-4C2E-8792-0B3ABC650C5CQ38485072-4A310469-0F14-4ACF-AFD6-CEAED3591268Q38682200-8E1613C4-2190-45CC-AE58-83E0C41995E7Q38763500-63D75431-B8FA-4A28-A60A-E4B26017F7F5Q38994357-F5B208E8-332A-4CC5-9DE3-B2A751038BEAQ40285797-71C7FF92-DFDD-410E-9137-AA9FC526510AQ41075630-A8BDE2D1-CEF8-4EBE-983F-A24429FEFA79Q41174367-701C3AA1-C441-495D-A2B1-F58C6BFDED79Q47573899-E5027DF5-9BCE-459B-9482-C0DB60901CF9Q47678068-B738E8B5-C6AB-4652-A510-D00CB939F371Q49023663-E603D3CA-0183-4BB5-BB40-234260FB7846Q53496298-9B4B75E2-7A68-4921-80D6-953F90951194Q64234875-16FA41F5-669E-4579-80B6-F04C33DC6EC1Q88124947-0D84A84D-F685-43C1-85A6-196EA68039B6Q89069076-53EC3418-0A48-4407-98EE-9A756DCAB4E1
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marco Monti
@ast
Marco Monti
@en
Marco Monti
@es
Marco Monti
@nl
type
label
Marco Monti
@ast
Marco Monti
@en
Marco Monti
@es
Marco Monti
@nl
prefLabel
Marco Monti
@ast
Marco Monti
@en
Marco Monti
@es
Marco Monti
@nl
P106
P1153
56657177800
P21
P31
P496
0000-0002-9592-1245